Stock of the Day

Seagen (SGEN)

$228.74

$0.00 (0.0%)

Market Cap: $42.93B

About Seagen

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.

The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Seagen Bull Case

Here are some ways that investors could benefit from investing in Seagen Inc.:

• Seagen Inc. is trading at a current stock price of $228.74, which is extremely close to its fifty-two-week high of $228.96, indicating strong recent momentum and investor confidence in the company's performance over the past year.
• The company maintains a perfect CEO approval rating of 1.00 out of 1.0 as of August 2026, suggesting that leadership under Clay B. Siegall is highly regarded by stakeholders and likely driving effective strategic execution.
• Seagen Inc. benefits from a diversified pipeline of antibody-drug conjugates (ADCs) and small molecule inhibitors, including ADCETRIS, PADCEV, and TUKYSA, which provide multiple revenue streams in the high-growth cancer therapy market.
• Strategic collaboration agreements with major pharmaceutical partners such as Takeda, Merck, and Genmab provide Seagen Inc. with significant financial support and expanded access to global markets for its therapeutic candidates.
• With a beta of 0.32, Seagen Inc. exhibits lower volatility compared to the broader market, which may appeal to investors seeking exposure to the biotechnology sector with potentially reduced short-term price swings.

Seagen Bear Case

Investors should be bearish about investing in Seagen Inc. for these reasons:

• Seagen Inc. has a negative P/E ratio of -57.04, indicating that the company is currently unprofitable, which means investors are paying for future growth potential rather than current earnings.
• The company pays no dividend, as indicated by a 0.00% dividend yield, which may be a drawback for income-focused investors who prefer regular cash distributions from their holdings.
• As a subsidiary of Pfizer Inc., Seagen Inc. may face potential strategic shifts or integration challenges that could impact its operational independence and long-term strategic direction.
• The biotechnology industry is highly competitive, and Seagen Inc. faces significant risk from new entrants and existing competitors developing similar cancer therapies, which could erode its market share.
• Regulatory risks remain a constant concern for biotechnology companies, as any delays or rejections in the approval process for new drug candidates could negatively impact Seagen Inc.'s revenue projections and stock price.